[go: up one dir, main page]

AR097202A1 - Composiciones farmacéuticas de ranolazina y dronedarona, procedimiento para elaborar tableta bicapa - Google Patents

Composiciones farmacéuticas de ranolazina y dronedarona, procedimiento para elaborar tableta bicapa

Info

Publication number
AR097202A1
AR097202A1 ARP140102908A ARP140102908A AR097202A1 AR 097202 A1 AR097202 A1 AR 097202A1 AR P140102908 A ARP140102908 A AR P140102908A AR P140102908 A ARP140102908 A AR P140102908A AR 097202 A1 AR097202 A1 AR 097202A1
Authority
AR
Argentina
Prior art keywords
ranolazine
dronedarone
bicapa
bilayer tablet
tablet
Prior art date
Application number
ARP140102908A
Other languages
English (en)
Inventor
Gerber Michael
Huang Neal
M Koziara Joanna
Zhang Feng
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AR097202A1 publication Critical patent/AR097202A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composición sólida que comprende ranolazina y una sal de ácido fosfórico de dronedarona secada por aspersión en una tableta bicapa. Reivindicación 1: Una tableta bicapa que comprende ranolazina y uno o más excipientes farmacéuticamente aceptables en una primera capa, y una formulación sólida estable de una sal de acido fosfórico secada por aspersión de dronedarona que además comprende HPMC E3 o HPMC E5 y uno o más excipientes farmacéuticamente aceptables en una segunda capa. Reivindicación 2: La tableta bicapa de acuerdo con la reivindicación 1, en donde la primera capa comprende una formulación de liberación sostenida de ranolazina. Reivindicación 7: La tableta bicapa de acuerdo con cualquiera de las reivindicaciones 1 a 6, que comprende entre aproximadamente 200 mg y aproximadamente 1500 mg de ranolazina y entre aproximadamente 50 mg y aproximadamente 400 mg de equivalente base de dronedarona de la formulación de una sal de ácido fosfórico secada por aspersión de dronedarona.
ARP140102908A 2013-08-02 2014-08-01 Composiciones farmacéuticas de ranolazina y dronedarona, procedimiento para elaborar tableta bicapa AR097202A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361861862P 2013-08-02 2013-08-02

Publications (1)

Publication Number Publication Date
AR097202A1 true AR097202A1 (es) 2016-02-24

Family

ID=51359424

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102908A AR097202A1 (es) 2013-08-02 2014-08-01 Composiciones farmacéuticas de ranolazina y dronedarona, procedimiento para elaborar tableta bicapa

Country Status (18)

Country Link
US (2) US20150037410A1 (es)
EP (1) EP3027175A1 (es)
JP (1) JP6141580B2 (es)
KR (1) KR20160027078A (es)
CN (1) CN105682642A (es)
AR (1) AR097202A1 (es)
AU (1) AU2014296378B2 (es)
BR (1) BR112016001779A2 (es)
CA (1) CA2919720A1 (es)
EA (1) EA201690216A1 (es)
HK (1) HK1225632A1 (es)
IL (1) IL243390A0 (es)
MX (1) MX2016001303A (es)
NZ (1) NZ715615A (es)
SG (1) SG11201600104VA (es)
TW (1) TW201536356A (es)
UY (1) UY35690A (es)
WO (1) WO2015017441A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018001582A1 (en) * 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
US10898444B2 (en) 2017-06-01 2021-01-26 Sun Pharmaceutical Industries Limited Extended release multiparticulates of ranolazine
CN112438955A (zh) * 2019-08-30 2021-03-05 深圳翰宇药业股份有限公司 一种雷诺嗪缓释组合物及其制备方法
CN110859843A (zh) * 2019-12-17 2020-03-06 卓和药业集团有限公司 一种治疗动脉硬化合并心绞痛的药物组合物及制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1814527T1 (sl) * 2004-11-05 2014-03-31 Boehringer Ingelheim International Gmbh Dvoslojna tableta, ki obsega telmisartan in amlodipin
TWI508726B (zh) * 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
CN102342907A (zh) * 2010-07-30 2012-02-08 江苏恒瑞医药股份有限公司 决奈达隆固体分散体及其制备方法
EP2605758A2 (en) * 2010-08-17 2013-06-26 Lupin Limited Controlled release formulations of dronedarone

Also Published As

Publication number Publication date
BR112016001779A2 (pt) 2017-08-01
CA2919720A1 (en) 2015-02-05
MX2016001303A (es) 2016-04-07
WO2015017441A1 (en) 2015-02-05
UY35690A (es) 2014-09-30
HK1225632A1 (zh) 2017-09-15
EP3027175A1 (en) 2016-06-08
TW201536356A (zh) 2015-10-01
KR20160027078A (ko) 2016-03-09
US20150037410A1 (en) 2015-02-05
US20160213569A1 (en) 2016-07-28
AU2014296378A1 (en) 2016-01-28
SG11201600104VA (en) 2016-02-26
EA201690216A1 (ru) 2016-08-31
JP6141580B2 (ja) 2017-06-07
AU2014296378B2 (en) 2017-03-30
CN105682642A (zh) 2016-06-15
JP2016525554A (ja) 2016-08-25
NZ715615A (en) 2017-06-30
IL243390A0 (en) 2016-02-29

Similar Documents

Publication Publication Date Title
CO2017012362A2 (es) Formas de dosificación sólida que comprenden palbociclib, un ácido hidrosoluble y un portador farmacéuticamente aceptable y métodos para su produccion y uso
ES2631980T3 (es) Formas de dosificación orales farmacéuticas que comprenden dabigatrán etexilato y sus sales farmacéuticamente aceptables
JOP20190108B1 (ar) تركيبات صيدلانية
AR089666A1 (es) Formulacion farmaceutica estable para administracion oral que comprende levocetirizina o una de sus sales aceptables desde el punto de vista farmaceutico, y montelukast o una de sus sales aceptables desde el punto de vista farmaceutico
IN2014MU01042A (es)
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
UY35091A (es) Formulaciones de liberacion modificada para oprozomib
AR097202A1 (es) Composiciones farmacéuticas de ranolazina y dronedarona, procedimiento para elaborar tableta bicapa
MX369742B (es) Formulación de liberación modificada.
EP2987786A4 (en) AMIDOPYRIDINOL DERIVATIVE OR PHARMACEUTICAL, SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS ACTIVE SUBSTANCE
EA202090913A1 (ru) Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
TR201722603A2 (tr) Metformi̇n ve si̇tagli̇pti̇n i̇çeren sicak eri̇tme ekstrüzyonu i̇le gerçekleşti̇ri̇len tablet formülasyonlari
ECSP16005208A (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
TR201310724A2 (tr) Linagliptinin farmasotik formulasyonları.
MX381175B (es) Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma.
MX2015015681A (es) Composicion farmaceutica que comprende fingolimod.
PE20150935A1 (es) Formulacion de comprimido compuesto de dos capas que comprende atorvastatina, irbesartan y carbonato de magnesio
CL2019001555A1 (es) Preparación farmacéutica y método para su fabricación.
UY35324A (es) Composiciones farmacéuticas que contienen dexketoprofeno y tramadol
MX2019005005A (es) Tableta de liberacion extendida que comprende un farmaco de perdida de peso.
AR099330A1 (es) Uso de paricalcitol en el tratamiento de la anemia inflamatoria
AR087155A1 (es) Formulacion granulada de azaperona de rapida disolucion
TH158486A (th) องค์ประกอบของยาปฏิชีวนะเซฟโทโลเซน
CU20130165A7 (es) Liberación modificada de 4-metil-3-[[-4-(3- piridinil)-2-pirimidinil]amino]-n-5-(4- metil-1h-imidazol-1- il)-3- (trifluorometil) fenil] benzamida solubilizada utilizando acidos orgánicos

Legal Events

Date Code Title Description
FB Suspension of granting procedure